Fifteen previously undescribed actinomycin analogs were isolated from the marine‑derived Streptomyces polyantibioticus strain S4D258. Structural characterization combined high‑resolution electrospray ionization mass spectrometry (HR‑ESIMS), nuclear magnetic resonance (NMR) spectroscopy, and Marfey's method to define amino acid residues and chromophore features. Two analogs, actinomycin H1 and H9, demonstrated antiproliferative activity against the triple‑negative breast cancer cell line MDA‑MB‑231, with reported IC50 values of 28.00 nM and 4.34 µM, respectively. Mechanistic studies on these two compounds revealed induction of S‑phase cell‑cycle arrest, mitochondrial membrane potential depolarization, apoptosis, and hallmarks of ferroptosis, including elevated reactive oxygen species (ROS), increased lipid peroxidation, and higher malondialdehyde (MDA) levels.
The study extracted and purified fifteen new actinomycin analogs from Streptomyces polyantibioticus S4D258. For structure elucidation the investigators applied a combination of analytical techniques: HR‑ESIMS provided high‑resolution molecular masses; NMR spectroscopy supplied detailed structural and connectivity information; and Marfey's method was used to assign absolute configurations of amino acid residues present in the peptides. The PubMed abstract reports these approaches as the basis for comprehensive structural assignment of the new compounds.
The isolated compounds were grouped by key structural motifs. Actinomycins H1–H5 (compounds 1–5) were reported to contain the residues L‑serine (L‑Ser), D‑2‑aminobutyric acid (D‑2‑Aba), and L‑2‑methylaminobutyric acid (L‑2‑MeAba). Actinomycin H6 (compound 6) was noted to include a 5H‑oxazolo[4,5‑b]phenoxazine chromophore, distinguishing it from the others. Actinomycins H7–H15 (compounds 7–15) were described as truncated analogs characterized by the presence of a single pentapeptidolactone unit rather than the full bicyclic peptide chromophore architecture. These structural variations expand the chemical diversity within natural actinomycins and provide distinct scaffolds for biological evaluation.
Biological screening against the triple‑negative breast cancer (TNBC) cell line MDA‑MB‑231 identified two active analogs. Actinomycin H1 inhibited cell proliferation with an IC50 of 28.00 nM, while actinomycin H9 showed activity with an IC50 of 4.34 µM. The PubMed abstract reports these potency values as measured against MDA‑MB‑231 cells. No additional IC50 values for other cell lines or in vivo efficacy data are reported in the abstract.
Mechanistic experiments performed on actinomycins H1 and H9 indicated multiple modes of cytotoxicity. Both analogs induced S‑phase cell‑cycle arrest. Mitochondrial membrane potential depolarization was observed, consistent with disruption of mitochondrial function. The compounds also induced apoptosis. In addition to apoptotic and mitochondrial effects, the authors report evidence of ferroptosis: treatment led to increases in intracellular reactive oxygen species (ROS), enhanced lipid peroxidation, and elevated levels of malondialdehyde (MDA), a lipid peroxidation product. These combined readouts support a mixed mechanism that includes both canonical apoptosis and ferroptotic processes.
The abstract specifies the principal biological readouts used to define mechanism: cell‑cycle distribution (S‑phase arrest), mitochondrial membrane potential assays (depolarization), apoptosis assays, and measurements consistent with ferroptosis (ROS, lipid peroxidation, and malondialdehyde). While the abstract summarizes these results, detailed experimental conditions, concentrations, time points, assay methodologies, and statistical analyses are provided in the full article and are not included in the PubMed abstract.
Collectively, the findings expand the known natural diversity of actinomycins by introducing 15 new analogs with distinct peptide and chromophore features. The identification of actinomycins H1 and H9 as inhibitors of MDA‑MB‑231 triple‑negative breast cancer cells, together with mechanistic evidence for S‑phase arrest, mitochondrial dysfunction, apoptosis, and ferroptosis, suggests these scaffolds warrant further evaluation as anticancer leads. The authors conclude that their results inspire re‑examination of actinomycin analogs for development against triple‑negative breast cancer. Specific experimental parameters, full spectra, and expanded biological data are reported in the original article; those methodological details were not reproduced in the abstract on PubMed.